Loading
ABL Diagnostics Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 30 Aug 2023.
ABL Diagnostics: what insiders have been doing
ABL Diagnostics is a Healthcare & Pharma company. Its directors and officers file their transactions with AMF. In the past year (18 October 2025 to 18 October 2026), 11 filings came from 1 insider.
The flow runs one way only: 8 sales worth €1.7M, from 1 insider, and no purchase. At €500k, the sale published on 2 February 2026 by ADVANCED BIOLOGICAL LABORATORIES SA Société Anonyme is the largest of the period.
For context, the typical company on the same exchange (median of 316 companies) published 6 filings over the same period, against 11 filings here. Since 2023, the database holds 2 purchases and 12 sales by insiders of the company.
Typically, a trade is published a median of 3 days after it takes place. For comparison, MAR article 19 gives managers three business days to notify a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from AMF. Past trades are no guide to future returns.
Insider Decl.
17
Thresholds
n/a
Buy Volume
€1,336
2 ops. · all time
Sell Volume
€3M
12 ops. · all time
Who traded when
BuySaleADVANCED BIOLOGICAL LABORATORIES SA Société Anonyme10 sales
Since the insiders bought
- -71.3%Entry €9.70 · Close at T+365 €2.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 9,916 of 24,148 companies
56.1
score / 100
Value34
Quality79
FCF yld1.8%
Earn yld2.4%
EV/EBITDA42.2x
ROE28%
Gross mgn95%
Net mgn14%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€2.54
Analyst consensus
Income statement
Revenue€7.0M
Gross profit€6.6M95% margin
EBITDA€1.0M15% margin
Net income€987k17.8% margin
Valuation
PER (trailing)21.2x
P/Book5.3x
Beta-0.53
Balance sheet & cash
Market cap€40.8M
Total debt€2.2M
Free Cash Flow€715k
Debt / Equity25%
Profitability & ownership
ROE28.2%
ROA7.8%
% insiders93.6%
% institutions0.0%
Last declaration on 31 August 2026
Declarations17 total
10,000 shares0ActionHors plateforme de négociationISIN FR001400AHX62026DD1135332
98,026 shares0ActionHors plateforme de négociationISIN FR001400AHX62026DD1132512
60,000 shares@ €2.500.39% mcap5.8% of flowActionHors plateforme de négociationISIN FR001400AHX62026DD1129675
65,616 shares@ €2.2860.39% mcap5.8% of flowActionHors plateforme de négociationISIN FR001400AHX62026DD1127827
62,308 shares@ €2.600.42% mcap6.3% of flowActionHors plateforme de négociationISIN FR001400AHX62026DD1125268
57,692 shares@ €2.600.39% mcap5.8% of flowActionHors plateforme de négociationISIN FR001400AHX62026DD1118776
51,900 shares@ €2.890.39% mcap5.8% of flowActionHors plateforme de négociationISIN FR001400AHX62026DD1117613
54,745 shares@ €2.740.39% mcap5.8% of flowActionHors plateforme de négociationISIN FR001400AHX62026DD1100972
128,026 shares@ €2.41612.0% of flowActionHors plateforme de négociationISIN FR001400AHX62026DD1094612
166,667 shares@ €3.0019.3% of flowActionHors plateforme de négociationISIN FR001400AHX62026DD1092130
128,026 shares0ActionHors plateforme de négociationISIN FR001400AHX62025DD1072556
166,667 shares@ €3.0019.3% of flowActionHors plateforme de négociationISIN FR001400AHX62025DD1050526
25,000 shares@ €5.505.3% of flowActionHors plateforme de négociationISIN FR001400AHX62025DD1021980
18,182 shares@ €5.503.9% of flowActionHors plateforme de négociationISIN FR001400AHX62024DD945614
▲
95 shares@ €4.8034.1% of flowActionEuronext ParisISIN FR001400AHX62023DD925593
Canonical exit: 3 Sept 2023 (T+90)
▲
100 shares@ €8.8065.9% of flowActionEuronext ParisISIN FR001400AHX62023DD925594
Canonical exit: 13 Nov 2023 (T+90)
23,287 shares@ €5.555.0% of flowActionHors plateforme de négociationISIN FR001400AHX62023DD925541
17 of 17 declarations
About ABL Diagnostics
ABL Diagnostics is a French molecular diagnostics company listed on Euronext Paris under ticker/ISIN FR001400AHX6. The group develops, manufactures and commercializes microbiology and molecular biology solutions for laboratories, hospitals and specialized healthcare providers focused on infectious diseases. Its business model sits in a high-value niche that combines diagnostic assays, sequencing-based genotyping tools and proprietary software, with a particularly strong focus on pathogen resistance profiling and patient follow-up.
The company’s roots date back to 2015, when ABL SA created ABL France, which later became the operational core of the diagnostic perimeter. ABL Diagnostics is now described as the listed subsidiary and sole publicly traded entity of the Luxembourg-based Advanced Biological Laboratories SA group. Over time, the group has built a proprietary technology platform around DeepChek®, then expanded into complementary molecular and digital solutions. It also established ABL USA Inc. to support commercialization in North America, while maintaining commercial reach across Europe, Africa and additional international markets.
Read moreShow less
DeepChek® is the flagship product family and central platform, based on Sanger sequencing and next-generation sequencing (NGS) for genotyping applications. It is used in particular for HIV, tuberculosis, hepatitis viruses and other infectious disease targets. The product suite also includes UltraGene®, which provides RT-PCR molecular detection solutions, as well as software and digital tools for analysis, data hosting, laboratory automation and the NADIS® computerized medical record. NADIS® is an important strategic asset: it is a specialty electronic health record designed for infectious disease patients and is reported by the company to be used in more than 200 hospitals in France and French-speaking Africa.
ABL Diagnostics targets an international market, with sales and partnership networks spanning France, Europe, French-speaking Africa and North America. The company emphasizes distributor partnerships and commercial expansion to broaden access to its assays and software worldwide. Its competitive position is that of a specialized integrated molecular diagnostics player, capable of bundling reagents, sequencing workflows, data tools and clinical follow-up software. Notable features of the business include recurring subscription revenue from NADIS® and a product focus on clinically relevant, high-need indications such as HIV and tuberculosis, where diagnostic precision, speed and treatment resistance monitoring remain essential.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
